相关实验视频

Updated: Jul 11, 2025

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

确定与线粒体相关的特征和分子亚型,以预测骨髓瘤的预后

Xiaokun Zhao¹, Jian Zhang¹, Jiahao Liu¹

¹Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, P.R. China.

|November 17, 2023

概括

这项研究确定了malonyl-CoA脱碳酶 (MLYCD) 作为骨髓瘤中关键的线粒体相关基因. 过度表达MLYCD可以抑制瘤生长,为骨髓瘤提供潜在的新治疗点.

科学领域:

在瘤学瘤学.
线粒体生物学线粒体生物学
遗传学是一个遗传学.

背景情况:

线粒体对骨髓瘤的发展和进展至关重要.
与线粒体相关的基因 (MRGs) 代表了理解骨髓瘤的潜在目标.
识别特定的MRG可以揭示新的诊断和治疗途径.

研究的目的:

为了研究线粒体相关基因 (MRG) 在骨髓瘤中的作用.
在MRG中确定新的预后生物标志物和治疗点.
探索MRG,瘤亚型和骨髓瘤中的免疫透之间的关系.

主要方法:

非负矩阵因子化 (NMF) 基于92个差异表达的MRG来分类骨髓瘤亚型.
单变量,LASSO和多变量考克斯回归分析,以构建预后风险模型.
单样样本基因组丰富分析 (ssGSEA) 用于评估免疫透特征.

主要成果:

骨髓瘤样本根据MRG表达被分为两个不同的亚型.
使用精选的MRG开发了一个预后风险模型.
马洛尼尔-CoA脱碳酶 (MLYCD) 被确定为骨髓瘤中显著下调的基因.
过度表达MLYCD抑制了骨髓瘤细胞的增殖,迁移和入侵.

结论:

MLYCD是骨髓瘤中潜在的瘤抑制剂.
已识别的MRG和预后模型提供了对骨髓瘤分子机制的见解.
MLYCD代表了一种有前途的生物标志物和治疗瘤治疗的治疗标.

关键词:

生物标志物生物标志物线粒体中的线粒体.分子亚型分子亚型骨质肉瘤是骨质肉瘤的一种疾病.预后签名预测签名

更多相关视频

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...